RTW Investments’s Neurogene NGNE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$27.5M Hold
1,362,456
0.27% 57
2025
Q4
$28.1M Hold
1,362,456
0.28% 56
2025
Q3
$23.6M Hold
1,362,456
0.29% 52
2025
Q2
$20.4M Buy
1,362,456
+13,800
+1% +$217K 0.29% 48
2025
Q1
$15.8M Sell
1,348,656
-1,600
-0.1% -$27.8K 0.24% 51
2024
Q4
$30.9M Buy
1,350,256
+215,000
+19% +$8M 0.47% 40
2024
Q3
$47.6M Buy
1,135,256
+64,691
+6% +$2.51M 0.69% 36
2024
Q2
$39M Buy
1,070,565
+301,443
+39% +$10.6M 0.6% 38
2024
Q1
$39.1M Buy
+769,122
New +$25.7M 0.58% 43

Other funds holding NGNE

RTW Investments's NGNE Position: Q1 2026 in Review

RTW Investments held its Neurogene (NGNE) position steady in Q1 2026 at 1,362,456 shares worth $27.5M. The position accounts for 0.27% of the portfolio, ranked #57.

RTW Investments first reported a position in NGNE in Q1 2024 and has held it in 9 quarters since. The position peaked at $47.6M in Q3 2024. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • RTW Investments held 1,362,456 shares of Neurogene worth $27.5M as of Q1 2026.
  • RTW Investments left its Neurogene share count unchanged in Q1 2026.
  • Neurogene made up 0.27% of RTW Investments's portfolio in Q1 2026, its #57 holding.
  • RTW Investments first reported a position in Neurogene in Q1 2024 and has held it in 9 quarters since.
  • RTW Investments's Neurogene position peaked at $47.6M in Q3 2024.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on RTW Investments's 13F filing for Q1 2026, filed 15 May 2026.